🇪🇺 Lyfnua in European Union

EMA authorised Lyfnua on 15 September 2023

Marketing authorisation

EMA — authorised 15 September 2023

  • Application: EMEA/H/C/005476
  • Marketing authorisation holder: Merck Sharp & Dohme B.V.
  • Local brand name: Lyfnua
  • Indication: Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.
  • Status: approved

Read official source →

Lyfnua in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Pain approved in European Union

Frequently asked questions

Is Lyfnua approved in European Union?

Yes. EMA authorised it on 15 September 2023.

Who is the marketing authorisation holder for Lyfnua in European Union?

Merck Sharp & Dohme B.V. holds the EU marketing authorisation.